Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857080 | 0.88 | PLK1 (0.52) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6855586 | 0.86 | PLK1 (0.50) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6850115 | 0.85 | PLK1 (0.48) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6849994 | 0.85 | PLK1 (0.48) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6854926 | 0.85 | PLK1 (0.46) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6850061 | 0.83 | L3MBTL1 (0.49) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6850183 | 0.82 | PLK1 (0.49) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6858394 | 0.82 | PLK1 (0.45) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6854083 | 0.82 | PLK1 (0.47) | ALDH1A1KDM4EHTTMAPTL3MBTL1 | |
| SCHEMBL6850125 | 0.81 | L3MBTL1 (0.48) | ALDH1A1KDM4EHTTMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | claimed |
| EP-1419159-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO 4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | claimed |
| WO-2003016314-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO[4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-02-27 | — | — | WO | claimed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | claimed |
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | disclosed |
| EP-1419159-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO 4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | disclosed |
| WO-2003016314-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO[4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | PDE3A, PDE4A, PDE5A | ALDH1A1 329/4885KDM4E 1483/4885HTT 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.